Erratum (DOI:10.1053/j.ajkd.2007.05.001);Serum Vitamin E and Oxidative Protein Modification in Hemodialysis: A Randomized Clinical Trial

American Journal of Kidney Diseases

Volumn 50, Issue 2, 2007, Pages 305-313

  Lu, Liang ^a   Erhard, Penny ^b   Salomon, Robert G ^a   Weiss, Miriam F ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

end stage renal disease; hemodialysis; hydroxynonenal; isolevuglandin; oxononenal; pentosidine; Vitamin E; tocopherol; tocopherol

Indexed keywords

4 HYDROXYNONENAL; ALPHA TOCOPHEROL; ERYTHROPOIETIN; IRON; LEVUGLANDIN E2; PENTOSIDINE; PLACEBO;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LIPID PEROXIDATION; MALE; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; OXIDATION; PROTEIN MODIFICATION; RANDOMIZED CONTROLLED TRIAL; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 34447635692     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.09.002     Document Type: Erratum

References (40)

1. Rimm E.B., Stampfer M.J., Ascherio A., Giovannucci E., Colditz G.A., and Willett W.C. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 328 (1993) 1450-1456
2. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione Trial. Lancet 354 (1999) 447-455
3. Lonn E., Bosch J., Yusuf S., et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial. JAMA 293 (2005) 1338-1347
4. Halliwell B. The antioxidant paradox. Lancet 355 (2000) 1179-1180
5. Himmelfarb J., Stenvinkel P., Ikizler T.A., and Hakim R.M. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62 (2002) 1524-1538
6. Islam K.N., O'Byrne D., Devaraj S., Palmer B., Grundy S.M., and Jialal I. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis 150 (2000) 217-224
7. Roob J.M., Khoschsorur G., Tiran A., Horina J.H., Holzer H., and Winklhofer-Roob B. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 11 (2000) 539-549
8. Boaz M., Smetana S., Weinstein T., et al. Secondary Prevention with Antioxidants of Cardiovascular disease in End stage renal disease (SPACE): Randomised placebo-controlled trial. Lancet 356 (2000) 1213-1218
9. Stephens N., Parsons A., Shofield P., et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347 (1996) 781-786
10. Landmesser U., Harrison D.G., and Drexler H. Oxidant stress-A major cause of reduced endothelial nitric oxide availability in cardiovascular disease. Eur J Clin Pharmacol 62 suppl 13 (2006) S13-S19
11. Ghiadoni L., Cupisti A., Huang Y., et al. Endothelial dysfunction and oxidative stress in chronic renal failure. J Nephrol 17 (2004) 512-519
12. Witting P.K., Upston J.M., and Stocker R. The molecular action of alpha-tocopherol in lipoprotein lipid peroxidation. Pro- and antioxidant activity of vitamin E in complex heterogeneous lipid emulsions. Subcell Biochem 30 (1998) 345-390
13. Weiss M., Erhard P., Kader-Attia F., et al. Mechanisms for the formation of advanced glycation end products (AGEs) in end stage renal disease (ESRD). Kidney Int 57 (2000) 2571-2585
14. Salomon R., Kaur K., and Batyreva E. Isolevuglandin-protein adducts in oxidized low density lipoprotein and human plasma: A strong connection with cardiovascular disease. Trends Cardiovasc Med 10 (2000) 53-59
15. Salomon R., Kaur K., Podrez E., Hoff H., Krushinsky A., and Sayre L. HNE-derived 2-pentylpyrroles are generated during oxidation of LDL, are more prevalent in blood plasma from patients with renal disease or atherosclerosis, and are present in atherosclerotic plaques. Chem Res Toxicol 13 (2000) 557-564
16. Ikizler T., Moroz J., Roberts L., et al. Plasma F2-isprostanes levels are elevated in chronic hemodialysis patients. Clin Nephrol 58 (2002) 190-197
17. Siems W., Quast S., Peter D., et al. Oxysterols are increased in plasma of end-stage renal disease patients. Kidney Blood Press Res 28 (2005) 302-306
18. Sommerburg O., Zang L.-Y., and van Kuijk F. Simultaneous detection of carotenoids and vitamin E in human plasma. J Chromatogr B 695 (1997) 209-215
19. Friedlander M., Wu Y., Elgawish A., and Monnier V. Early and advanced glycosylation end products: Kinetics of formation and clearance in peritoneal dialysis. J Clin Invest 97 (1996) 728-735
20. 2, a product of the isoprostane pathway, in oxidized low density lipoprotein. J Biol Chem 274 (1999) 20271-20280
21. Girndt M., Lengler S., Kaul H., Sester U., Sester M., and Kohler H. Prospective crossover trial of the influence of vitamin-E coated dialyzer membranes on T-cell activation and cytokine induction. Am J Kidney Dis 35 (2000) 95-104
22. Schwing W., Erhard P., Hollamon C., et al. Thrombotic events and markers of oxidation and inflammation in hemodialysis. Hemodialysis Int 8 (2004) 338-343
23. Himmelfarb J., Kane J., McMonagle E., et al. Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease. Kidney Int 64 (2003) 978-991
24. Smith K.S., Lee C.L., Ridlington J.W., Leonard S.W., Devaraj S., and Traber M.G. Vitamin E supplementation increases circulating vitamin E metabolites tenfold in end-stage renal disease patients. Lipids 38 (2003) 813-819
25. Galli F., Buoncristiani U., Conte C., Aisa C., and Floridi A. Vitamin E in uremia and dialysis patients. Ann N Y Acad Sci 1031 (2004) 348-351
26. Handelman G.J., Epstein W.L., Peerson J., Spiegelman D., Machlin L.J., and Dratz E.A. Human adipose alpha-tocopherol and gamma-tocopherol kinetics during and after 1 y of alpha-tocopherol supplementation. Am J Clin Nutr 59 (1994) 1025-1032
27. Saldeen T., Li D., and Mehta J.L. Differential effects of alpha- and gamma-tocopherol on low-density lipoprotein oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis. J Am Coll Cardiol 34 (1999) 1208-1215
28. Burton G.W., and Ingold K.U. Autoxidation of biological molecules. 1. The antioxidant activity of vitamin E and related chain-breaking phenolic antioxidants in vitro. J Am Chem Soc 103 (1981) 6472-6477
29. Yamauchi R., Ozaki K., Shimoyamada M., and Kato K. Iron-catalyzed reaction products of alpha-tocopherol with 1-palmitoyl-2-linoleoyl-3-sn-phosphatidylcholine (13S)-hydroperoxide. Chem Phys Lipids 114 (2002) 193-201
30. Yamauchi R., Yagi Y., and Kato K. Oxidation of alpha-tocopherol during the peroxidation of dilinoleoylphosphatidylcholine in liposomes. Biosci Biotechnol Biochem 60 (1996) 616-620
31. Zhang R., Brennan M.L., Shen Z., et al. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem 277 (2002) 46116-46122
32. Poliakov E., Brennan M.L., Macpherson J., et al. Isolevuglandins, a novel class of isoprostenoid derivatives, function as integrated sensors of oxidant stress and are generated by myeloperoxidase in vivo. FASEB J 17 (2003) 2209-2220
33. Brennan M.L., and Hazen S.L. Amino acid and protein oxidation in cardiovascular disease. Amino Acids 25 (2003) 365-374
34. x and complements a-tocopherol: Physiological implications. Proc Natl Acad Sci U S A 94 (1997) 3217-3222
35. Jiang Q., Elson-Schwab I., Courtemanche C., and Ames B.N. Gamma-tocopherol and its major metabolite, in contrast to alpha-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci U S A 97 (2000) 11494-11499
36. Devaraj S., and Jialal I. Failure of vitamin E in clinical trials: Is gamma-tocopherol the answer?. Nutr Rev 63 (2005) 290-293
37. Himmelfarb J., and Hakim R.M. Oxidative stress in uremia. Curr Opin Nephrol Hypertens 12 (2003) 593-598
38. Wanner C., Bahner U., Mattern R., Lang D., and Passlick-Deetjen J. Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients. Nephrol Dial Transplant 19 (2004) 2570-2575
39. Baragetti I., Furiani S., Vettoretti S., et al. Role of vitamin E-coated membrane in reducing advanced glycation end products in hemodialysis patients: A pilot study. Blood Purif 24 (2006) 369-376
40. Odetti P., Traverso N., Monacelli F., et al. Vitamin E-coated filter decreases levels of free 4-hydroxyl-2-nonenal during haemodialysis sessions. Free Radic Res 40 (2006) 207-212